Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses pharmacists' educational needs on biosimilars.
Transcript:
I think it's not just pharmacists. It's the overall healthcare team and provider team. Right now I think we're still in a new and emerging area. Hopefully, shortly we’ll also see biosimilar insulin on the market, too, and that’ll be a great discussion; that’s a big topic right now in the biosimilar area.
For pharmacists, I think there needs to be a lot more discussion on how drugs are getting approved, what is the regulatory process: phase 1, phase 3. We also need to go over and delineate a lot more discussion on the global implementation of biosimilars to help provide more of a foundation for discussions here in the [United States, US].
Other areas which are requiring a lot more education: [continuing education, CE], review articles as well to get the information out there in the next few years. We need more discussion on [pharmacy and therapeutics, P and T] implementation, how that works. Reimbursement is going to be critical in this area, and there is a pure lack of understanding of reimbursement.
In fact, if there's one thing that can be done, it’s to create a level playing field for the understanding of reimbursement, both from a private payer and also government payer type of situation to make sure everyone is on the same page. I feel the more we talk about this, the more the education goes on on this, it will only help better provide resources for patients, but also institutions. So pharmacists really need to be aware of that as well.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.